FDA requires black-box warning on post-chemo anemia drugs

Makers of drugs used to treat patients with anemia that results from kidney failure or chemotherapy must add a black-box warning due to recent studies suggesting possible heart problems or death, the FDA says. The agency issued the new requirement for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit, which are genetically engineered forms of erythropoietin.

View Full Article in:

NYTimes.com · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care